-
1.发明公开
公开(公告)号：EP0698015A1
公开(公告)日：1996-02-28
申请号：EP94917338.0
申请日：1994-05-10
发明人： MARSTERS, James, C., Jr. , BROWN, Michael, S. , CROWLEY, Craig, W. , GOLDSTEIN, Joseph, L. , JAMES, Guy, L. , McDOWELL, Robert, S. , OARE, David , RAWSON, Thomas, E. , REYNOLDS, Mark , SOMERS, Todd, G.
IPC分类号： A61K31 , A61P31 , A61P35 , C07D223 , C07D243 , C07D401 , C07D403 , C07D405 , C07D409 , C07D417 , C07D487 , C07D498 , C07D513 , C07K5 , A61K38
CPC分类号： C07D223/16 , A61K38/00 , C07D243/10 , C07D243/24 , C07D401/06 , C07D401/14 , C07D403/06 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/06 , C07D409/14 , C07D487/04 , C07D513/04 , C07K5/0207 , C07K5/0606 , C07K5/06139 , C07K5/06191 , C07K5/081 , C07K5/0821 , C07K5/0827 , C07K5/1013 , C07K5/1024 , C07K5/1027
摘要： Benzodiazepine derivatives are disclosed that act as potent inhibitors of ras farnesyl:protein transferase. Pharmaceutical compositions containing these benzodiazepines are provided for treatment of diseases for which inhibition of the ras farnesyl:protein transferase is indicated.
-
公开(公告)号：EP0792289A1
公开(公告)日：1997-09-03
申请号：EP95940028.0
申请日：1995-11-16
申请人： GENENTECH, INC.
发明人： SOMERS, Todd, C. , ELIAS, Kathleen, A. , CLARK, Ross, G. , McDOWELL, Robert, S. , STANLEY, Mark, S. , BURNIER, John, P. , RAWSON, Thomas, E.
IPC分类号： C07D295 , A61K31 , A61K38 , A61P3 , A61P5 , C07D209 , C07D211 , C07D401 , C07D403 , C07K5 , C07K7 , C07K14
CPC分类号： C07D401/12 , A61K38/00 , C07D209/20 , C07D211/62 , C07D403/12 , C07K5/0202 , C07K5/0205 , C07K5/0207 , C07K5/06078 , C07K5/0812 , C07K5/1016 , C07K5/1024 , C07K7/06 , C07K14/60
摘要： The present invention comprises growth hormone releasing peptides/peptidomimetics (GHRP) capable of causing release of growth hormone from the pituitary. Compositions containing the GHRP's of this invention are used to promote growth in mammals either alone or in combination with other growth promoting compounds, especially IGF-1. In a method of this invention GHRP's in combination with IGF-1 are used to treat Type II diabetes. An exemplary compound (1) of this invention is provided above.
-
公开(公告)号：EP0728147B1
公开(公告)日：2003-02-12
申请号：EP95901112.3
申请日：1994-11-04
申请人： GENENTECH, INC.
摘要： Human receptor selective atrial natriuretic factor variants containing various substitutions, especially G16R, show equal potency and binding affinity for the human A-receptor but have decreased affinity for the human clearance or C-receptor. These ANF variants have natriuretic, diuretic and vasorelaxant activity but have increased metabolic stability, making them suitable for treating congestive heart failure, acute kidney failure and renal hypertension.
-
公开(公告)号：EP0792289B1
公开(公告)日：2000-07-12
申请号：EP95940028.4
申请日：1995-11-16
申请人： GENENTECH, INC.
发明人： SOMERS, Todd, C. , ELIAS, Kathleen, A. , CLARK, Ross, G. , McDOWELL, Robert, S. , STANLEY, Mark, S. , BURNIER, John, P. , RAWSON, Thomas, E.
CPC分类号： C07D401/12 , A61K38/00 , C07D209/20 , C07D211/62 , C07D403/12 , C07K5/0202 , C07K5/0205 , C07K5/0207 , C07K5/06078 , C07K5/0812 , C07K5/1016 , C07K5/1024 , C07K7/06 , C07K14/60
摘要： The present invention comprises growth hormone releasing peptides/peptidomimetics (GHRP) capable of causing release of growth hormone from the pituitary. Compositions containing the GHRP's of this invention are used to promote growth in mammals either alone or in combination with other growth promoting compounds, especially IGF-1. In a method of this invention GHRP's in combination with IGF-1 are used to treat Type II diabetes. An exemplary compound (1) of this invention is provided above.
-
公开(公告)号：EP0728147A1
公开(公告)日：1996-08-28
申请号：EP95901112.0
申请日：1994-11-04
申请人： GENENTECH, INC.
IPC分类号： C12N15 , A61K38 , A61P1 , A61P3 , A61P7 , A61P9 , A61P13 , A61P15 , C07H21 , C07K14 , C12P21 , C12R1
摘要： Human receptor selective atrial natriuretic factor variants containing various substitutions, especially G16R, show equal potency and binding affinity for the human A-receptor but have decreased affinity for the human clearance or C-receptor. These ANF variants have natriuretic, diuretic and vasorelaxant activity but have increased metabolic stability, making them suitable for treating congestive heart failure, acute kidney failure and renal hypertension.
-
-
-
-
搜索结果
5 条记录 (耗时 0.016 秒)
